Under construction – not a live service
Sign in
Taking peoplePhase 3

Tests admilparant in adults with idiopathic pulmonary fibrosis

Compares admilparant with placebo in adults with idiopathic pulmonary fibrosis, a lung scarring disease.

Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

Key facts

Where
Ancona, Bergamo, Bologna, Florence, Foggia, Forli', Milan, Modena, Monza, Napoli, Palermo, Pavia, Pisa, Rome, Sassari, and Siena, ItalySee the 17 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 or older with idiopathic pulmonary fibrosis (IPF), a scarring lung disease. It compares admilparant (BMS-986278) with a placebo.

Age
40 years or older
Sex
Women and men can join.
Disease stage
IPF diagnosed within 7 years before screening, confirmed by a chest HRCT scan showing usual interstitial pneumonia.
Earlier treatment
If taking pirfenidone or nintedanib, the dose must have been stable for at least 90 days before screening. If not taking them, the person must not have had either in the 28 days before screening.

Main reasons for not taking part

  • Stroke or transient ischemic attack within 3 months before screening
  • Symptoms of heart failure at rest
  • Current cancer, or earlier cancer with less than 2 years free of recurrence
  • Interstitial lung disease with a known primary cause, such as hypersensitivity pneumonitis, autoimmune-related ILD or sarcoidosis

Read by machine on 9 November 2026.

Where in Italy

  • Azienda Ospedaliero-Universitaria delle MarcheAncona, ItalyNo longer taking part
  • Azienda Ospedaliera Papa Giovanni XXIIIBergamo, ItalyNo longer taking part
  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoBologna, ItalyNo longer taking part
  • Careggi University HospitalFlorence, ItalyNo longer taking part
  • Azienda Ospedaliero Universitaria Ospedali Riuniti-Policlinico di Foggia-Ospedale C. D'AvanzoFoggia, ItalyNo longer taking part
  • Ospedale Giovan Battista Morgagni-Luigi Pierantoni Di ForlìForli', ItalyNo longer taking part
  • Azienda Sociosanitaria Territoriale Santi Paolo E CarloMilan, ItalyNo longer taking part
  • Fondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoMilan, ItalyNo longer taking part
  • Azienda Ospedaliero - Universitaria di ModenaModena, ItalyNo longer taking part
  • Fondazione IRCCS San Gerardo dei TintoriMonza, ItalyNo longer taking part
  • Azienda Ospedaliera Dei Colli-Ospedale Colli MonaldiNapoli, ItalyNo longer taking part
  • Istituto Mediterraneo Per I Trapianti E Terapie Ad Alta Specializzazione S.r.l.Palermo, ItalyNo longer taking part
  • Fondazione IRCCS Policlinico San MatteoPavia, ItalyNo longer taking part
  • Azienda Ospedaliero Universitaria PisanaPisa, ItalyNo longer taking part
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, ItalyNo longer taking part
  • Azienda Ospedaliero-Universitaria di SassariSassari, ItalyNo longer taking part
  • Azienda Ospedaliera Universitaria SeneseSiena, ItalyNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Trial details

Who runs it
Bristol-Myers Squibb Services Unlimited Company
Trial code
EU 2023-503697-21-01
Record updated
30 September 2026
Original description
To evaluate the efficacy of admilparant compared to placebo (PBO) in demonstrating improvement in absolute change in Forced Vital Capacity (FVC) from baseline at Week 52.Read full original descriptionShow less

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

To evaluate the efficacy of admilparant compared to placebo (PBO) in demonstrating improvement in absolute change in Forced Vital Capacity (FVC) from baseline at Week 52.

Inclusion: Subjects with IPF aged ≥ 40 years at the time of signing the informed consent; Diagnosis of IPF within 7 years prior to screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained at screening and verification of usual interstitial pneumonia; If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening; If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening; Women who are of childbearing potential must have a highly effective form of contraception and must provide a negative urine/serum pregnancy test at screening and predose; Men who are sexually active with women of childbearing potential agree to use male barrier contraception.

Exclusion: History of stroke or transient ischemic attack within 3 months prior to screening; Exhibit symptoms of heart failure at rest; Participants who have: 1) a current malignancy, 2) a previous malignancy with less than 2 years free of recurrence; 3) a biopsy that is suspicious for malignancy and the possibility of malignancy cannot be ruled out; Interstitial Lung Disease (ILD) associated with known primary causes (eg.hypersensitivity pneumonitis,autoimmune associated ILD,sarcoidosis,etc.).

EU CTIS 2023-503697-21-01